Drug Profile
Ebdarokimab - Akeso Biopharma
Alternative Names: AK-101Latest Information Update: 23 Jan 2024
Price :
$50
*
At a glance
- Originator Akeso Biopharma
- Class Anti-inflammatories; Antipsoriatics; Antirheumatics; Monoclonal antibodies; Skin disorder therapies
- Mechanism of Action Interleukin 12 inhibitors; Interleukin 23 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Registered Plaque psoriasis
- Phase I Ulcerative colitis
- Preclinical Systemic lupus erythematosus
- No development reported Crohn's disease; Psoriatic arthritis
Most Recent Events
- 23 Jan 2024 Ebdarokimab is still in phase I trial for Ulcerative colitis in USA and China (SC) (Akeso Biopharma pipeline, January 2024)
- 23 Jan 2024 Akeso Biopharma completes a phase I trial in Ulcerative colitis in USA and China (SC) prior to January 2024 (Akeso Biopharma pipeline, January 2024)
- 24 Aug 2023 Registered for Plaque psoriasis in China (SC)